Background: We sought to identify genomic alterations (GAs) in salivary mucoepidermoid carcinomas.
Introduction
Malignant salivary gland carcinomas (SGCs) are rare cancers with a wide range of histotypes according to the World Health Organization's (WHO) Classification of SGCs [1] . Mucoepidermoid carcinomas (MECs) are the most common SGC among adults, comprising $35% of new diagnoses [2, 3] . The prognosis for patients with MECs is based upon stage and tumor grade, with advanced stage and/or high-grade tumors having significantly worse overall survival compared with their low grade, less advanced counterparts [3, 4] . Unfortunately, the preferred treatment in the curative intent setting in under debate, and therapies for relapsed/metastatic cases are notoriously ineffective [5, 6] .
In recent years, a translocation between CTRC1, a CREBregulated transcription co-activator, and MAML2, a Notch receptor-induced transcription co-activator, has been identified in MECs [7] . Pre-clinical data suggests that this translocation is oncogenic [8] . CRTC1/MAML2 translocations are seen in 50%-65% of MECs, with a higher percentage found in low-and intermediate-grade tumors, though it is not clear if the translocation is associated with survival [9] [10] [11] . Beyond CRTC1/MAML2 translocations little is known about MEC's genomic profile. Three studies utilizing next generation sequencing (NGS) on a combined 31 MECs identified alterations in TP53, the PI3K signaling pathway, and NF1 [11] [12] [13] . There are also limited immunohistochemistry (IHC) data in MECs. They frequently express high levels of EGFR (45%) and MUC1 (44%) on the cell surface [14] . HER2 IHC staining or ERBB2 gene amplification has been reported in a low number of MECs (0%-14%) and appears independent of CTRC1/MAML2 translocation [14, 15] . Given MECs poor prognosis in the relapsed/metastatic setting, new targets are required for precision therapy.
In the following study, we used comprehensive genomic profiling (CGP) to survey a large group of clinically advanced MECs to search for novel therapy targets and demonstrate the impact of biomarker selected targeted therapy in selected cases.
Patients and methods
Approval for this study was obtained from the Western Institutional Review Board (Protocol No. 20152817). A full description of the methods can be found in the supplementary methods, available at Annals of Oncology online. SGC samples submitted for commercial CGP as MECs underwent central pathologic confirmation. Cases of other WHO SGC categories were excluded. DNA was extracted from formalin-fixed and paraffin-embedded samples. Hybrid-captured libraries were sequenced to a median exon coverage depth of 600Â for up to 315 genes, and resultant sequences were analyzed for base substitutions, short insertions/ deletions, copy number alterations (focal amplifications and homozygous deletions) and gene fusions/rearrangements, as previously described [16] . Tumor mutational burden (TMB) was calculated as previously described (supplementary methods, available at Annals of Oncology online) [17] . Statistical analysis was performed with the Fisher exact test with the level of significance set at P 0.05 using JMP (SAS, Cary, NC).
Results
Of the 48 patient samples included in this study, high-grade MECs were most common (N ¼ 25, 52.1%) followed by intermediate (N ¼ 16, 33.3%) and low (N ¼ 7, 14.6%). The median age of all patients was 56.5 years and there was no significant correlation between age and tumor grade (P ¼ 0.1) ( Table 1 ). There were more men (58.3%) than women in the data set but there was no significant difference in gender distribution between tumor grades (P ¼ 0.329). The tumor source from which samples were obtained did not differ significantly between grades with most samples taken from the parotid gland (35.4%) followed by salivary gland, NOS (12.5%), and soft tissue (12.5%) (P ¼ 0.221). The majority of tissue samples came from local/regional sites (parotid, salivary gland, head/neck, larynx, mouth, tongue, trachea) (60.4%) versus metastatic sites (39.6%).
A total of 183 GAs were found in 80 unique genes ( Table 2 ; Figures 1 and 2) . Base substitutions or short indels comprised 54 (29.5%) GAs, 23 (12%) were amplifications, 35 (19.1%) were homozygous deletions, 8 (4.4%) were rearrangements or fusions, and 64 (35%) were gene truncations. The mean number of GAs per sample was 3.8 6 3.1 with high-grade tumors having more GAs per sample (5 6 3.8) than other grade tumors (P ¼ 0.019). The majority of patients (46/48, 95.8%) had at least one GA identified.
The most common GAs were seen in CDKN2A (N ¼ 20, 41.6%) and TP53 (N ¼ 19, 39.6%) (Figures 1 and 2 ; supplemen tary Table S1 , available at Annals of Oncology online). Other genes altered in !10% of specimens included CDKN2B (N ¼ 14, 29. , and high-grade (36%) tumors (P ¼ 0.069). CKDN2B GAs were always accompanied by CKDN2A GAs. A BAP1 mutation was seen in the youngest patient in this study (26 years) but there was not a significant difference in mean ages between BAP1 GA (50.8 years) versus BAP1 wild-type (58.8 years) patients (P ¼ 0.093). There was also not a significant difference in BAP1
GAs between tumor grade (P ¼ 0.131). Only one tumor harboring a BAP1 GAs also had a TP53 GA. Other notable GAs were identified in small numbers (Figures 1  and 2 ). NOTCH1/2 and NF1 GAs were each seen in 4.3% of samples. One FLT3 mutation and one BRAF V600E were identified in low-grade MECs. EGFR gene amplification was identified in one high-grade MEC. Other GAs are shown in Figure 2 and supple mentary Table S1 , available at Annals of Oncology online. The TMB amongst MECs was low with only 5 (10%) of cases exceeding a TMB of greater than 10 mutations/Mb of sequenced DNA.
Discussion
Mucoepidermoid carcinomas are the most common salivary gland carcinomas, yet their genomic underpinnings are largely unknown. In this study, we described the genomic landscape of MECs, identifying recurring genomic alterations including some that may allow for precision therapy selection. To our knowledge, TERT  STK11  SOX2  RB1  PTEN  PIK3CA  NUP93  NF1  MLL2  MAP3K1  LRP1B  HRAS  Gene  FGFR1  FBXW7  FAT1  ERBB2  EP300  CTNNB1  CREBBP  CDKN2B  CDKN2A  BRCA2  BRCA1  BAP1  ATM  ARID2   0% 10% 20% 30% Percent 40% 50% Figure 1 . Comparison of genes with >1 genetic alterations in mucoepidermoid carcinomas. this is the most comprehensive study examining the genetic profiles of these tumors. Overall, MECs have a distinct mutation profile compared to other SGCs. In total, MECs have a similar number of GAs per tumor to adenocarcinomas, NOS and salivary duct carcinomas (SDCs), and a greater number than adenoid cystic carcinomas (ACCs) [18, 19] . Like the high-grade adenocarcinomas, NOS and SDCs, TP53 mutations and cyclin family GAs were common [12, 19] . Distinct from adenocarcinoma, NOS and SDCs, however, ERBB2 amplification was a relatively uncommon event in MECs, occurring in less than 10% of tumors compared with 33% of SDCs and 15% of adenocarcinomas, NOS [19, 20] . The rate of ERBB2 amplification in this study is similar to previously reported HER2 IHC positivity and ERBB2 GA rates [14, 21] . PI3K pathway activation was common in high grade but less common in low-grade tumors. This compares to the disparity seen in other SGCs, such as SDCs (54%) and adenocarcinoma, NOS (32%), and ACCs (<5%) [18, 19] . Prior reports have identified mutations in TP53 and PIK3CA in MECs using NGS; however, the two other NGS-based investigations evaluated 31 MEC combined cases whereas this study comprises 48 [11] [12] [13] .
Moreover, our study evaluates a larger number of genes than the prior reports.
One key finding of this paper is the difference in genomic profiles between tumor grades. High-grade MECs have significantly worse overall survival than low-or intermediate-grade tumors [4, 22] . Our data suggest that this may be due to high-grade tumors' greater genetic complexity. Compared to low (2.3 6 1.4) and intermediate (2.8 6 1.5) grade tumors, high-grade tumors had more mean GAs (5 6 3.8). Prior studies have suggested that high-grade MECs have more global chromosomal abnormalities than low-or intermediate-grade tumors [10, 23] . Moreover, high-grade tumors had more TP53 GAs than low-or intermediate-grade MECs. The high incidence of TP53 mutations is consistent with a recent NGS-based study of 18 MECs [11] . Novel to this investigation, high-grade tumors had a greater frequency of both PIK3CA GAs and PI3K pathway activation than lower grade MECs. PI3K pathway inhibition is an active area of therapeutic investigation, and PI3K/mTOR inhibitors may be more effective in tumors with PI3K/mTOR pathway activation [24, 25] .
Our study identified frequent alterations in DNA repair genes. Over 20% of tumors in this series had GAs in BAP1
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Intermediate High   TP53  CDKN2B  PIK3CA  BAP1  HRAS  ERBB2  BRCA2  TERT  MAP3K1  LRP1B  FGFR1  FAT1  STK11  SOX2  RB1  PTEN  NUP93  NF1  MLL2  FBXW7  EP300  CTNNB1  CREBBP  BRCA1  ATM  ARID2  TGFBR2  TERC  SPTA1  SPEN  RICTOR  PRKC1  PREX2  PIK3R2  PARP4  PALB2  NTRK3  NOTCH2  NOTCH1  MYST3  MYCL1  MYC  MITF  MDM2  MAP2K1  MAGI2  LYN  KRAS  KEL  KDM6A  KDMSC  JUN  MNF1A  GNAS  GATA4  FRS2  FLT3  FGF4  FGF3  FGF19  FANCA  EWSR1  ERRFI1  ERG  EPHB1  EPHA3  EGFR  DNMT3A  CYLD  CHEK2  CDKN1B  CDKN12  CCNE1  CCND1  BRAF  BARD1  ASXL1  ARID1A (BRCA1-associated protein 1) and 10% harbored BRCA GAs. BAP1 is a nuclear localized deubiquinating enzyme that functions as a tumor suppressor, controlling transcription regulation, cell cycling, and DNA damage repair [26] . BAP1 is commonly altered in sporadic melanoma (up to 22%), renal cell carcinoma (RCC) (17%), and mesothelioma (50%) [27] [28] [29] [30] , but rarely seen in other SGCs [12, 19, 31] . As observed in sarcomatoid RCCs, there was little overlap between BAP1 and TP53 GAs in MECs in this study [30] . Interestingly, germline mutations in BAP1 are associated with an autosomal dominant cancer syndrome marked by increased risk for melanoma, mesothelioma, and RCC, among other tumors [28, 32] . Accordingly, there is one report of a BAP1 germline mutant developing a MEC [33] . Similarly, BRCA GAs are uncommon in other SGC histologies but were seen in over 10% of samples in this study [12, 19, 31] . BRCA GAs may be targeted by PARP inhibitors, raising the possibility of a novel therapeutic target for MECs [34] . Moreover, there are preliminary data to suggest that individuals harboring germline BRCA GAs may be at higher risk of developing SGCs [35] . The presence of BAP1 and BRCA GAs in our MEC dataset is intriguing; however, as this study did not evaluate germline mutations, any postulated correlation between BAP1 or BRCA germline mutations and MEC development is speculative. The association between these genes and MECs is worth exploring in future studies.
Other common and rare GAs were identified that may have therapeutic and prognostic value. While we found ERBB2 amplification to be less common than in other SGCs, ERBB2 may be targeted by anti-HER2 agents when present [36, 37] . This study also identified GAs in genes with precision drugs currently commercially available and in later stage of development. For instance, one BRAF V600E was identified, as were FGF pathway targets. This may also provide prognostic value, as FGFR1 GAs have been associated with worse prognosis in SGCs [23] . These findings suggest CGP may help identify GAs for therapeutic exploitation in difficult to treat cases. Beyond specific genes, the low TMB observed in this MEC cohort suggests that immune checkpoint inhibitors may not be highly effective for these tumors. Although extensive data regarding checkpoint inhibition for MECs are lacking, and the role of PD-1/PD-L1 IHC testing in MECs limited, data from other tumors suggest high-mutational burdens and/or PD-1/PD-L1 IHC are predictive of response to checkpoint inhibitors [38] . We look forward to the results of checkpoint inhibitor studies in SGCs.
This study has limitations. The greatest limitation is the lack of clinical correlations between identified GAs and disease characteristics or patient outcomes. As this study was a retrospective evaluation of samples submitted for clinical care, data about cancer stage, response to therapies, and patient survival are not available. As mentioned above, the lack of germline mutational analysis hinders one's ability to associate MEC development and BAP1 or BRCA-related cancer syndromes. Another limitation is that, while the CGP platform used in this study covers a wide range of genes, there may be clinically relevant GAs that were not assessed. Most importantly, this assay does not assess for the CRTC1/MAML2 translocation often seen in MECs. Other studies suggest these translocations are less common in high-grade tumors, and while a recent study combining NGS and fluorescence in situ hybridization (FISH) appear to support this finding, but we cannot assess it here [7, 9, 11] . Another limitation is that the cancers tested in this study may not represent the genomic spectrum of these diagnoses, as commercial CGP tends to be performed on more aggressive, advanced/metastatic tumors [39] . Lastly, while this study demonstrates frequent actionable GAs, it does not address intratumoral heterogeneity and the relative importance of each GA in patient outcomes. Determining the inciting GA and relative importance of subsequent GAs in SGC is worth exploring in future studies. Despite these limitations, this study greatly contributes to the knowledge of the genetic drivers of these rare tumors.
In summary, deep genomic profiling with a CGP assay of mucoepidermoid carcinomas identified potentially actionable GAs that can influence therapy selection and direct patients to enter clinical trials using precision therapies.
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